Drugs / Decoy20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05651022 | Feb 2023 → Jun 2027 expected | colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma +2 | Indaptus Therapeutics, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decoy20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05651022 ↗ |
| Action | Activate | “TLR agonist-based” NCT05651022 ↗ |
| Modality | Other / unclassified | “multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy” NCT05651022 ↗ |
| Route | Other | “systemically administered” NCT05651022 ↗ |